"On behalf of the Board of Directors, I want to thank him for his work and leadership over the last three years. Martin has since he joined navigated the company through a strategic transition and established a solid platform for the further development of bemcentinib. On behalf of the company, I wish him all the best in his new endeavors", said Anders Tullgren, Chairman of BerGenBio.

The Board of Directors has initiated a succession process and will actively work with the management to support and review the business requirements.

"I have thoroughly enjoyed my past three years at BerGenBio. It has been a privilege to lead the company and contribute to developing a medicine that can potentially be of great importance to a large number of patients. The company has a very competent team and an exciting time ahead, and I will follow its path and progress closely," said Martin Olin.

Anders Tullgren
Chairman of the Board of Directors

Contact requests through:

ir@bergenbio.com

or

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com

or

Jan Lilleby
jl@lillebyfrisch.no

+47 90 55 16 98

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including cancer and severe respiratory infections. The Company is focused on its proprietary lead candidate, bemcentinib, a potentially first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC and severe respiratory infections. BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more information, visit www.bergenbio.com

This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act.